5.13

0.19% -0.010

After Hours: 5.31 0.18 +3.51%

Sana Biotechnology Inc (SANA)

Overview News Price History Option Chain Financials Why SANA Down? Discussions Forecast

Sana Biotechnology Inc stock is traded at $5.13, with a volume of 6.56M. It is down -0.19% in the last 24 hours and up +72.73% over the past month. Sana Biotechnology Inc is a biotechnology company. The company develops engineered cells as medicines and therapies to treat diseases. It is engaged in developing cell engineering programs for across a broad array of therapeutic areas with unmet treatment needs, including oncology, diabetes, B-cell-mediated autoimmune, and central nervous system (CNS) disorders, among others. Its pipeline of product candidates is comprised of SC291, SC262, SC255, UP421 and others.

Previous Close:

$5.14

Open:

$5.25

24h Volume:

6.56M

Relative Volume:

1.46

Market Cap:

$1.16B

Revenue:

Net Income/Loss:

$-283.26M

P/E Ratio:

-3.4898

EPS:

-1.47

Net Cash Flow:

$-273.61M

1W Performance:

+15.28%

1M Performance:

+72.73%

6M Performance:

+51.78%

1Y Performance:

-16.18%

1-Day Range:

$5.05

$5.33

1-Week Range:

$4.165

$5.33

52-Week Range:

$1.26

$7.30

Sana Biotechnology Inc Stock (SANA) Company Profile

Name

Sana Biotechnology Inc

Sector

Healthcare (1162)

Industry

Biotechnology (651)

Phone

(206) 701-7914

Address

188 EAST BLAINE STREET, SUITE 400, SEATTLE

Employee

194

Twitter

Next Earnings Date

2025-03-17

Latest SEC Filings

SANA's Discussions on Twitter

Compare SANA with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
SANA Sana Biotechnology Inc	5.13	1.16B	0	-283.26M	-273.61M	-1.47
VRTX Vertex Pharmaceuticals Inc	472.27	120.73B	11.10B	-988.90M	-1.26B	-3.92
REGN Regeneron Pharmaceuticals Inc	564.64	61.80B	14.09B	4.50B	2.96B	39.28
ALNY Alnylam Pharmaceuticals Inc	328.00	42.46B	2.35B	-269.70M	-75.39M	-2.09
ARGX Argen X Se Adr	591.74	35.22B	2.58B	1.06B	-1.28B	16.33
ONC Beone Medicines Ltd Adr	296.46	31.99B	3.81B	-644.79M	-669.77M	-6.24

Sana Biotechnology Inc Stock (SANA) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jul-03-25	Resumed	Morgan Stanley	Overweight
Mar-18-25	Upgrade	Citizens JMP	Mkt Perform → Mkt Outperform
Mar-14-25	Initiated	Jefferies	Buy
Jan-08-25	Upgrade	TD Cowen	Hold → Buy
Nov-05-24	Downgrade	JMP Securities	Mkt Outperform → Mkt Perform
Jun-26-24	Initiated	Rodman & Renshaw	Buy
Jan-16-24	Upgrade	H.C. Wainwright	Neutral → Buy
Sep-25-23	Initiated	JMP Securities	Mkt Outperform
Sep-05-23	Initiated	Citigroup	Buy
Aug-14-23	Initiated	TD Cowen	Market Perform
May-02-23	Initiated	H.C. Wainwright	Neutral
Mar-01-21	Initiated	BofA Securities	Buy
Mar-01-21	Initiated	Goldman	Neutral
Mar-01-21	Initiated	JP Morgan	Neutral
Mar-01-21	Initiated	Morgan Stanley	Overweight

View All

Sana Biotechnology Inc Stock (SANA) Latest News

Jul 23, 2025

What analysts say about Sana Biotechnology Inc. stockExplosive portfolio gains - Autocar Professional

Jul 23, 2025

Citi Maintained a Buy Rating on Sana Biotechnology (SANA) - MSN

Jul 23, 2025

Sana Biotechnology Inc. Stock Analysis and ForecastHigh-velocity capital appreciation - jammulinksnews.com

Jul 23, 2025

Is Sana Biotechnology Inc. a good long term investmentFree Stock Chart Pattern Guide - Autocar Professional

Jul 23, 2025

Jul 22, 2025

11 Best American Penny Stocks to Buy According to Analysts - Insider Monkey

Jul 22, 2025

Sana Biotechnology (SANA) Stock Surges on Positive Type 1 Diabetes Treatment Results - MSN

Jul 22, 2025

Jul 21, 2025

Commit To Purchase Sana Biotechnology At $2.50, Earn 28% Using Options - Nasdaq

Jul 21, 2025

Jul 19, 2025

What drives Sana Biotechnology Inc. stock priceMassive profits - jammulinksnews.com

Jul 19, 2025

Jul 15, 2025

Draig Therapeutics Appoints Experienced Biotech Leader Douglas E. Williams, Ph.D. as Chair of its Board of Directors - GlobeNewswire Inc.

Jul 15, 2025

Jul 14, 2025

How To Trade This 150% Gainer Chasing A Cure For Type 1 Diabetes - Benzinga

Jul 14, 2025

Jul 13, 2025